RLMD vs. PMVP, ACET, CTXR, CRVS, CNTB, CLRB, ALLK, RZLT, ABEO, and IMUX
Should you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include PMV Pharmaceuticals (PMVP), Adicet Bio (ACET), Citius Pharmaceuticals (CTXR), Corvus Pharmaceuticals (CRVS), Connect Biopharma (CNTB), Cellectar Biosciences (CLRB), Allakos (ALLK), Rezolute (RZLT), Abeona Therapeutics (ABEO), and Immunic (IMUX). These companies are all part of the "pharmaceutical preparations" industry.
PMV Pharmaceuticals (NASDAQ:PMVP) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, PMV Pharmaceuticals had 15 more articles in the media than Relmada Therapeutics. MarketBeat recorded 19 mentions for PMV Pharmaceuticals and 4 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.77 beat PMV Pharmaceuticals' score of 0.58 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.
PMV Pharmaceuticals received 4 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 58.82% of users gave PMV Pharmaceuticals an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
PMV Pharmaceuticals currently has a consensus target price of $5.75, indicating a potential upside of 173.81%. Relmada Therapeutics has a consensus target price of $25.00, indicating a potential upside of 648.50%. Given PMV Pharmaceuticals' higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than PMV Pharmaceuticals.
90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 18.0% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Relmada Therapeutics' return on equity of -29.14% beat PMV Pharmaceuticals' return on equity.
PMV Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.
Summary
PMV Pharmaceuticals beats Relmada Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Relmada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relmada Therapeutics Competitors List
Related Companies and Tools
